Candel Therapeutics (CADL) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Candel Therapeutics (CADL) is Neutral.

The composite score behind that read is -0.18, weighing +0.11 of bullish evidence against -0.28 bearish.

Candel Therapeutics last closed at $9.87, -3.52% on the session.

Against the IVW growth benchmark the position is -4.13% over the forecast window.

The read is built from 11 underlying insights — 3 bullish and 8 bearish.

Agreement across those insights is 73%.

Candel Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Candel Therapeutics in the 12th percentile on return on equity, where 100 is best.

Candel Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $782.79M.

StockMap tracks Candel Therapeutics as the 145th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite Candel Therapeutics ranks 133rd of 365 in the group, against a group median of -0.21.